JP2022512726A5 - - Google Patents

Info

Publication number
JP2022512726A5
JP2022512726A5 JP2021521097A JP2021521097A JP2022512726A5 JP 2022512726 A5 JP2022512726 A5 JP 2022512726A5 JP 2021521097 A JP2021521097 A JP 2021521097A JP 2021521097 A JP2021521097 A JP 2021521097A JP 2022512726 A5 JP2022512726 A5 JP 2022512726A5
Authority
JP
Japan
Prior art keywords
construct
nucleic acid
polypeptide
vector
acid construct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021521097A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512726A (ja
JP7593920B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/057084 external-priority patent/WO2020082041A1/en
Publication of JP2022512726A publication Critical patent/JP2022512726A/ja
Publication of JP2022512726A5 publication Critical patent/JP2022512726A5/ja
Priority to JP2024203045A priority Critical patent/JP2025028917A/ja
Application granted granted Critical
Publication of JP7593920B2 publication Critical patent/JP7593920B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021521097A 2018-10-18 2019-10-18 核酸構築物及び使用方法 Active JP7593920B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024203045A JP2025028917A (ja) 2018-10-18 2024-11-21 核酸構築物及び使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862747393P 2018-10-18 2018-10-18
US62/747,393 2018-10-18
US201962840343P 2019-04-29 2019-04-29
US62/840,343 2019-04-29
PCT/US2019/057084 WO2020082041A1 (en) 2018-10-18 2019-10-18 Nucleic acid constructs and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024203045A Division JP2025028917A (ja) 2018-10-18 2024-11-21 核酸構築物及び使用方法

Publications (3)

Publication Number Publication Date
JP2022512726A JP2022512726A (ja) 2022-02-07
JP2022512726A5 true JP2022512726A5 (cg-RX-API-DMAC7.html) 2022-10-26
JP7593920B2 JP7593920B2 (ja) 2024-12-03

Family

ID=68503214

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021521097A Active JP7593920B2 (ja) 2018-10-18 2019-10-18 核酸構築物及び使用方法
JP2024203045A Pending JP2025028917A (ja) 2018-10-18 2024-11-21 核酸構築物及び使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024203045A Pending JP2025028917A (ja) 2018-10-18 2024-11-21 核酸構築物及び使用方法

Country Status (17)

Country Link
US (2) US20200268906A1 (cg-RX-API-DMAC7.html)
EP (2) EP3867376A1 (cg-RX-API-DMAC7.html)
JP (2) JP7593920B2 (cg-RX-API-DMAC7.html)
KR (2) KR102957630B1 (cg-RX-API-DMAC7.html)
CN (1) CN113272428A (cg-RX-API-DMAC7.html)
AU (2) AU2019360269A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021007323A2 (cg-RX-API-DMAC7.html)
CA (1) CA3116580A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021006362A2 (cg-RX-API-DMAC7.html)
IL (2) IL322336A (cg-RX-API-DMAC7.html)
MA (1) MA53919A (cg-RX-API-DMAC7.html)
MX (1) MX2021004282A (cg-RX-API-DMAC7.html)
MY (1) MY208708A (cg-RX-API-DMAC7.html)
PH (1) PH12021550843A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202103732RA (cg-RX-API-DMAC7.html)
TW (1) TW202028461A (cg-RX-API-DMAC7.html)
WO (1) WO2020082041A1 (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL326835A (en) 2018-10-16 2026-04-01 Blueallele Llc Methods for targeted insertion of dna genes
JP7578590B2 (ja) 2018-10-18 2024-11-06 インテリア セラピューティクス,インコーポレーテッド 第ix因子を発現するための組成物及び方法
CN113939595A (zh) 2019-06-07 2022-01-14 瑞泽恩制药公司 包括人源化白蛋白基因座的非人动物
US12521451B2 (en) 2019-11-08 2026-01-13 Regeneron Pharmaceuticals, Inc. CRISPR and AAV strategies for x-linked juvenile retinoschisis therapy
CA3231712A1 (en) 2021-09-08 2023-03-16 Flagship Pioneering Innovations Vi, Llc Pah-modulating compositions and methods
KR20240099358A (ko) 2021-10-27 2024-06-28 리제너론 파마슈티칼스 인코포레이티드 B형 혈우병 치료를 위한 인자 ix를 발현하기 위한 조성물 및 방법
EP4423271A2 (en) 2021-10-28 2024-09-04 Regeneron Pharmaceuticals, Inc. Crispr/cas-related methods and compositions for knocking out c5
US20250051749A1 (en) * 2021-12-24 2025-02-13 Toolgen Incorporated Novel promoter and use thereof
IL314482A (en) 2022-02-02 2024-09-01 Regeneron Pharma Anti-tfr:gaa and anti-cd63:gaa insertions for treatment of pompe disease
WO2023212677A2 (en) 2022-04-29 2023-11-02 Regeneron Pharmaceuticals, Inc. Identification of tissue-specific extragenic safe harbors for gene therapy approaches
AU2023269134A1 (en) 2022-05-09 2024-12-12 Regeneron Pharmaceuticals, Inc. Vectors and methods for in vivo antibody production
WO2023235725A2 (en) 2022-05-31 2023-12-07 Regeneron Pharmaceuticals, Inc. Crispr-based therapeutics for c9orf72 repeat expansion disease
WO2023235726A2 (en) 2022-05-31 2023-12-07 Regeneron Pharmaceuticals, Inc. Crispr interference therapeutics for c9orf72 repeat expansion disease
CN120659627A (zh) 2022-07-29 2025-09-16 瑞泽恩制药公司 用于转铁蛋白受体(tfr)介导的脑和肌肉递送的组合物和方法
KR20250075694A (ko) 2022-09-28 2025-05-28 리제너론 파마슈티칼스 인코포레이티드 세포 기반 요법을 강화하기 위한 항체 저항성 변형 수용체
AU2023371614A1 (en) 2022-11-04 2025-05-15 Regeneron Pharmaceuticals, Inc. Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
AU2023379457A1 (en) 2022-11-14 2025-05-15 Regeneron Pharmaceuticals, Inc. Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
US20250002946A1 (en) 2023-06-30 2025-01-02 Regeneron Pharmaceuticals, Inc. Methods And Compositions For Increasing Homology-Directed Repair
IL326018A (en) 2023-07-28 2026-03-01 Regeneron Pharma Introduction of anti-TFR:GAA and anti-CD63:GAA for the treatment of Pompe disease
AR133384A1 (es) 2023-07-28 2025-09-24 Regeneron Pharma Anti-tfr:esfingomielinasa ácida para el tratamiento de la deficiencia de esfingomielinasa ácida
AU2024315073A1 (en) 2023-07-28 2026-01-22 Regeneron Pharmaceuticals, Inc. Use of bgh-sv40l tandem polya to enhance transgene expression during unidirectional gene insertion
EP4771049A1 (en) 2023-08-28 2026-07-08 Regeneron Pharmaceuticals, Inc. Cxcr4 antibody-resistant modified receptors
WO2025072816A2 (en) * 2023-09-29 2025-04-03 The Board Of Regents Of The University Of Texas System Endogenous nucleus targeting signal peptides and uses thereof
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025160340A2 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
WO2025235388A1 (en) 2024-05-06 2025-11-13 Regeneron Pharmaceuticals, Inc. Transgene genomic identification by nuclease-mediated long read sequencing
WO2025265017A1 (en) 2024-06-20 2025-12-26 Regeneron Pharmaceuticals, Inc. Ass1 gene insertion for the treatment of citrullinemia type i
WO2026072529A1 (en) 2024-09-24 2026-04-02 University Of Florida Research Foundation, Incorporated Mettl7a for improved embryo competence

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5585481A (en) 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
ATE515510T1 (de) 1991-12-24 2011-07-15 Isis Pharmaceuticals Inc Durch dna-abschnitte unterbrochene modifizierte oligonukleotide
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
CA2186118C (en) 1994-03-23 2010-10-19 Richard W. Hanson Compacted nucleic acids and their delivery to cells
EP0760008A1 (en) 1994-05-19 1997-03-05 Dako A/S Pna probes for detection of neisseria gonorrhoeae and chlamydia trachomatis
US7951925B2 (en) 2006-05-25 2011-05-31 Sangamo Biosciences, Inc. Methods and compositions for gene inactivation
US8110379B2 (en) 2007-04-26 2012-02-07 Sangamo Biosciences, Inc. Targeted integration into the PPP1R12C locus
CA2720903C (en) 2008-04-14 2019-01-15 Sangamo Biosciences, Inc. Linear donor constructs for targeted integration
JP5908725B2 (ja) 2008-08-22 2016-04-26 サンガモ バイオサイエンシーズ, インコーポレイテッド 標的一本鎖開裂および標的組込みのための方法、並びに組成物
EP3156494B8 (en) 2008-12-04 2018-09-19 Sangamo Therapeutics, Inc. Genome editing in rats using zinc-finger nucleases
US9255259B2 (en) 2010-02-09 2016-02-09 Sangamo Biosciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
US9567573B2 (en) 2010-04-26 2017-02-14 Sangamo Biosciences, Inc. Genome editing of a Rosa locus using nucleases
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit
EP2758529B1 (en) 2011-09-21 2019-03-20 Sangamo Therapeutics, Inc. Methods and compositions for regulation of transgene expression
US9222105B2 (en) 2011-10-27 2015-12-29 Sangamo Biosciences, Inc. Methods and compositions for modification of the HPRT locus
ES2728782T3 (es) 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
US8946460B2 (en) * 2012-06-15 2015-02-03 Commonwealth Scientific And Industrial Research Organisation Process for producing polyunsaturated fatty acids in an esterified form
HUE051612T2 (hu) * 2012-07-11 2021-03-01 Sangamo Therapeutics Inc Eljárások és készítmények lizoszomális tárolási betegségek kezelésére
EP4397759A3 (en) 2012-10-23 2024-10-09 Toolgen Incorporated Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
ES2887254T3 (es) 2013-03-08 2021-12-22 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
US10059655B2 (en) 2013-12-19 2018-08-28 Novartis Ag Lipids and lipid compositions for the delivery of active agents
CN106794141B (zh) 2014-07-16 2021-05-28 诺华股份有限公司 将核酸包封在脂质纳米粒主体中的方法
CN113337533A (zh) 2014-12-23 2021-09-03 先正达参股股份有限公司 用于鉴定和富集包含位点特异性基因组修饰的细胞的方法和组合物
AU2016226077B2 (en) 2015-03-03 2021-12-23 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases with altered PAM specificity
WO2017093804A2 (en) 2015-12-01 2017-06-08 Crispr Therapeutics Ag Materials and methods for treatment of alpha-1 antitrypsin deficiency
ES3030658T3 (en) 2016-03-30 2025-07-01 Intellia Therapeutics Inc Lipid nanoparticle formulations for crispr/cas components
IL311278B2 (en) 2017-09-29 2026-05-01 Intellia Therapeutics Inc Polynucleotides, compositions, and methods for genome editing
IL326835A (en) 2018-10-16 2026-04-01 Blueallele Llc Methods for targeted insertion of dna genes

Similar Documents

Publication Publication Date Title
Wagner et al. Synthetic biology: emerging concepts to design and advance adeno‐associated viral vectors for gene therapy
JP7832262B2 (ja) 肝特異的ウイルスプロモーター及びその使用方法
JP2020019772A5 (cg-RX-API-DMAC7.html)
JP2022508182A5 (cg-RX-API-DMAC7.html)
JP2024009857A5 (cg-RX-API-DMAC7.html)
JP2022529631A5 (cg-RX-API-DMAC7.html)
JP2020114235A5 (cg-RX-API-DMAC7.html)
JP2022511348A5 (cg-RX-API-DMAC7.html)
AU2019363593A1 (en) AAV triple-plasmid system
JP2022505381A5 (cg-RX-API-DMAC7.html)
JP2022516004A5 (cg-RX-API-DMAC7.html)
JP2022524434A5 (cg-RX-API-DMAC7.html)
JP2020519284A5 (cg-RX-API-DMAC7.html)
JP2018522529A5 (cg-RX-API-DMAC7.html)
JP2020500541A5 (cg-RX-API-DMAC7.html)
JP2022525302A5 (cg-RX-API-DMAC7.html)
JP2021534814A5 (cg-RX-API-DMAC7.html)
JP2024508696A5 (cg-RX-API-DMAC7.html)
JP2022553573A5 (cg-RX-API-DMAC7.html)
JP2022551744A5 (cg-RX-API-DMAC7.html)
JP2024508696A (ja) Rnaアデノ随伴ウイルス(raav)ベクター及びその用途
JP2023537358A5 (cg-RX-API-DMAC7.html)
CA3223506A1 (en) Methods and compositions for tau reduction gene therapy
CN120548368A (zh) 用于正确包装重复元件的腺相关病毒载体
JP2020519294A5 (cg-RX-API-DMAC7.html)